Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
fda
4
×
life sciences
national blog main
san francisco blog main
4
×
boston top stories
clinical trials
national top stories
san francisco top stories
boston
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
investing
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
accent therapeutics
aducanumab
akouos
alder biopharmaceuticals
alzheimer's disease
amblyotech
What
fda
4
×
medicines
4
×
drug
approval
developing
ipo
new
activity
affects
americans
amgen
approvals
approved
bio
biogen
blueprint
cancer
candidate
candidates
clamped
class
covid
currently
date
delays
developed
economic
fast
frequency
gets
head
hearing
including
isn’t
loss
lot
marketing
meds
migraine
millions
Language
unset
Current search:
fda
×
biotech
×
medicines
×
" san francisco blog main "
×
fda
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
